{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:36:48Z","timestamp":1781311008337,"version":"3.54.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The effectiveness and safety of the instillation of botulinum toxin A (BTX-A) remain subjects of controversy. The meta-analysis was performed to assess the efficacy and safety of a novel intravesical instillation of BTX-A for managing overactive bladder (OAB) or interstitial cystitis\/bladder pain syndrome (IC\/BPS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>The randomized controlled trials were retrieved from PubMed, EMBASE, and the Cochrane Library databases up to 29 January 2024. The studies included in the analysis focused on the intravesical instillation of BTX-A in patients with OAB or IC\/BPS. The data extraction was independently conducted by two reviewers. The random effects model was utilized for the assessment in order to compute the overall effect sizes. The heterogeneity tests and subgroup analyses were conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The meta-analysis and subgroup analysis did not reveal any statistically significant differences. However, the results of the meta-analysis indicated that intravesical instillation of BTX-A could reduce episodes of urgency urinary incontinence (UUI) (overall weighted mean difference [WMD] = \u22120.85; 95% confidence interval [CI]: -2.99 to 1.29). In subgroup analysis, an increase in void volume (VV) at 4 weeks of follow-up (WMD = \u221231.99; 95% CI: -70.53 to 6.54) was observed compared to that at 12 weeks (WMD = \u22121.73; 95% CI: -16.98 to 13.53). In contrast to the groups receiving more than 200 units of BTX-A, patients in the group receiving 200 units or fewer of BTX-A (WMD = \u221216.89; 95% CI: -41.14 to 7.35) exhibited a significantly greater increase in VV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conslusion<\/jats:title><jats:p>The intravesical instillation of BTX-A appears to be a viable administration route that may reduce UUI and VV to some extent. In terms of safety, intravesical instillation of BTX-A demonstrated a reduced risk of UTI and post-void residual compared to the placebo group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024517877<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1586845","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T05:22:08Z","timestamp":1744694528000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety and efficacy of intravesical instillation of botulinum toxin-A in the treatment of interstitial cystitis\/bladder pain syndrome and overactive bladder: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Yongheng","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zitian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinggang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1046\/j.1526-4610.43.7s.3.x","article-title":"Evidence for antinociceptive activity of botulinum toxin type A in pain management","volume":"43","author":"Aoki","year":"2003","journal-title":"Headache"},{"key":"B2","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1097\/ju.0000000000002800","article-title":"Intravesical instillation of OnabotulinumtoxinA in the treatment of refractory overactive bladder in participants with urinary incontinence","volume":"208","author":"Chermansky","year":"2022","journal-title":"J. Urol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/j.juro.2014.07.008","article-title":"Bladder instillation of liposome encapsulated onabotulinumtoxina improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial","volume":"192","author":"Chuang","year":"2014","journal-title":"J. Urol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.juro.2017.02.021","article-title":"A prospective, multicenter, double-blind, randomized trial of bladder instillation of liposome formulation OnabotulinumtoxinA for interstitial cystitis\/bladder pain syndrome","volume":"198","author":"Chuang","year":"2017","journal-title":"J. Urol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.juro.2009.03.083","article-title":"Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes","volume":"182","author":"Chuang","year":"","journal-title":"J. Urol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.eururo.2008.05.007","article-title":"Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and suppresses bladder hyperactivity in cyclophosphamide-induced cystitis in rats","volume":"56","author":"Chuang","year":"","journal-title":"Eur. Urol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1159\/000351037","article-title":"Botulinum toxin-A injections for idiopathic overactive bladder: a systematic review and meta-analysis","volume":"91","author":"Cui","year":"2013","journal-title":"Urol. Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1177\/13524585231174580","article-title":"Intravesical injections of botulinum neurotoxin A to treat overactive bladder and\/or detrusor overactivity related to multiple sclerosis: 5-Year continuation rate and specific risk factors for discontinuation-A study from the neuro-urology committee of the French Association of Urology","volume":"29","author":"Delaval","year":"2023","journal-title":"Mult. Scler."},{"key":"B9","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/nau.24820","article-title":"Evaluation of the effect of 100U of Onabotulinum toxin A on detrusor contractility in women with idiopathic OAB: a multicentre prospective study","volume":"41","author":"De Rienzo","year":"2022","journal-title":"Neurourol. Urodyn."},{"key":"B10","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1007\/s12325-023-02625-8","article-title":"Patient and clinician challenges with anticholinergic step therapy in the treatment of overactive bladder: a narrative review","volume":"40","author":"Dmochowski","year":"2023","journal-title":"Adv. Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/nau.23072","article-title":"A standard for terminology in chronic pelvic pain syndromes: a report from the chronic pelvic pain working group of the international continence society","volume":"36","author":"Doggweiler","year":"2017","journal-title":"Neurourol. Urodyn."},{"key":"B12","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1146\/annurev-biochem-013118-111654","article-title":"Botulinum and tetanus neurotoxins","volume":"88","author":"Dong","year":"2019","journal-title":"Annu. Rev. Biochem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/s0022-5347(17)42717-0","article-title":"Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients","volume":"139","author":"Dykstra","year":"1988","journal-title":"J. Urol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"114218","DOI":"10.1016\/j.yexcr.2024.114218","article-title":"Mechanosensitive Piezo1 channels promote neurogenic bladder fibrosis via regulating TGF-\u03b21\/smad and Hippo\/YAP1 pathways","volume":"442","author":"Feng","year":"2024","journal-title":"Exp. Cell Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1093\/gerona\/glab241","article-title":"Use of benzodiazepines and risk of incident dementia: a retrospective cohort study","volume":"77","author":"Gerlach","year":"2022","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3390\/toxins11090510","article-title":"Botulinum neurotoxin A intravesical injections in interstitial cystitis\/bladder painful syndrome: a systematic review with meta-analysis","volume":"11","author":"Giannantoni","year":"2019","journal-title":"Toxins (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.juro.2015.01.087","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment","volume":"193","author":"Gormley","year":"2015","journal-title":"J. Urol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/nau.20687","article-title":"Status of international consensus on interstitial cystitis\/bladder pain syndrome\/painful bladder syndrome: 2008 snapshot","volume":"28","author":"Hanno","year":"2009","journal-title":"Neurourol. Urodyn."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/ans.19309","article-title":"Botulinum toxin A for the treatment of neurogenic bladder in children: a systematic review and meta-analysis","author":"He","year":"2024","journal-title":"ANZ J. Surg."},{"key":"B20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.36076\/ppj.2013\/16\/291","article-title":"Central sensitization in urogynecological chronic pelvic pain: a systematic literature review","volume":"16","author":"Kaya","year":"2013","journal-title":"Pain Physician"},{"key":"B21","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3109\/21681805.2015.1121406","article-title":"Intravesical instillation of onabotulinum toxin A embedded in inert hydrogel in the treatment of idiopathic overactive bladder: a double-blind randomized pilot study","volume":"50","author":"Krhut","year":"2016","journal-title":"Scand. J. Urol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s11255-010-9790-z","article-title":"Intravesical instillation of botulinum toxin A: an in vivo murine study and pilot clinical trial","volume":"43","author":"Krhut","year":"2011","journal-title":"Int. Urol. Nephrol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3390\/toxins14070498","article-title":"Clinical application of botulinum neurotoxin in lower-urinary-tract diseases and dysfunctions: where are we now and what more can we do?","volume":"14","author":"Kuo","year":"2022","journal-title":"Toxins (Basel)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.eururo.2014.01.036","article-title":"Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study","volume":"65","author":"Kuo","year":"2014","journal-title":"Eur. Urol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"840695","DOI":"10.3389\/fphar.2022.840695","article-title":"Hengli(\u00ae) Chinese botulinum toxin type A for treatment of patients with overactive bladder: a multicenter, prospective, randomized, double-blind, placebo-controlled trial","volume":"13","author":"Liao","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"Bmj"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat. Methods Med. Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.eururo.2013.08.031","article-title":"Global prevalence and economic burden of urgency urinary incontinence: a systematic review","volume":"65","author":"Milsom","year":"2014","journal-title":"Eur. Urol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1080\/13697137.2018.1552254","article-title":"Managing overactive bladder","volume":"22","author":"Robinson","year":"2019","journal-title":"Climacteric"},{"key":"B30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/s0022-3565(25)31908-7","article-title":"Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction","volume":"212","author":"Simpson","year":"1980","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.urology.2008.01.028","article-title":"Urinary glycosaminoglycans as biomarker for urothelial injury: is it possible to discriminate damage from recovery?","volume":"72","author":"Soler","year":"2008","journal-title":"Urology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1021\/mp060001j","article-title":"Recent advances in intravesical drug\/gene delivery","volume":"3","author":"Tyagi","year":"2006","journal-title":"Mol. Pharm."},{"key":"B33","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e021889","DOI":"10.1136\/bmjopen-2018-021889","article-title":"Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review","volume":"8","author":"Yeowell","year":"2018","journal-title":"BMJ Open"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1586845\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T05:22:13Z","timestamp":1744694533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1586845\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":34,"alternative-id":["10.3389\/fphar.2025.1586845"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1586845","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"article-number":"1586845"}}